Innovation

Tedopi®’s originality resides in the combination of neo-epitopes (fragments of tumor associated antigens) which are:

  • Chemically optimized in order to uniquely target malignant cells
  • Combined to amplify the immune response

Tedopi®, based on Memopi® technology, in Phase 3 clinical trial in advanced lung cancer

Tedopi® is intended for use in non-small cell lung cancer (NSCLC), stimulates T cytotoxic “killer” cells and relearns them to spot malignant cells for eliminatation. That is the immunosurveillance process.
Tedopi® is a patented combination of neo-10 epitopes selected and optimized from five tumorous antigens.
View Science & technologies

These 10 neo-epitopes generate a specific response from the T cytotoxic cells against the malignant cells, which express at least one of these tumorous antigens. The selected epitopes are chemically optimized and combined to avoid any phenomenon of immune tolerance. Tedopi® is a personalized treatment for HLA-A2+ patients, a key receptor for the cytotoxic T-immune response.
The goal is to stabilize the development of the disease and to extend patients’ lives.

Data from the Phase 2 clinical trial showed that Tedopi® was effective in treating NSCLC by increasing patients’ relative survival rate.

View Clinical trials

  • Tedopi® is currently in a Phase 3 registration study, Atalante 1, in Europe and the U.S. The study is aimed at evaluating the benefits of Tedopi® as compared to current standard chemotherapies (docetaxel or pemetrexed, both approved in 2nd line treatment) in HLA-A2 positive patients diagnosed with stage IIIB (locally advanced) or IV (metastatic) NSCLC. The trial is expected to be completed in 2018. For additional information about the Atalante 1 trial and to learn more about eligibility, patients can visit: https://clinicaltrials.gov/ct2/show/NCT02654587.
  • A Phase 2 clinical trial with Tedopi® in combination with a checkpoint inhibitor, for the treatment of lung cancer, is slated to begin in 2017, in partnership with a European research organization.
  • New cancer indications involving a strong medical need – ovarian, colon, triple negative breast cancer, brain metastasis, mesothelioma – will be considered for partnering The five tumor antigens targeted by the 10 neo-epitopes have been selected because they are a factor of poor prognosis in several types of cancers, and in particular, in advanced stage cancers.
  • Tedopi® in NSCLC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and is a Personalized Medicine in Europe in HLA-A2 positive patients.